Compare DLTH & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLTH | NYXH |
|---|---|---|
| Founded | 1989 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | 154 |
| Industry | Clothing/Shoe/Accessory Stores | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.7M | 142.3M |
| IPO Year | 2015 | 2021 |
| Metric | DLTH | NYXH |
|---|---|---|
| Price | $3.05 | $3.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.00 | ★ $9.33 |
| AVG Volume (30 Days) | ★ 68.2K | 25.1K |
| Earning Date | 06-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.12 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $565,184,000.00 | N/A |
| Revenue This Year | N/A | $213.98 |
| Revenue Next Year | $2.80 | $126.25 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.72 | $2.76 |
| 52 Week High | $4.66 | $8.64 |
| Indicator | DLTH | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 42.68 | 56.05 |
| Support Level | $2.76 | $2.80 |
| Resistance Level | $3.31 | $3.37 |
| Average True Range (ATR) | 0.20 | 0.12 |
| MACD | -0.06 | 0.05 |
| Stochastic Oscillator | 6.00 | 93.68 |
Duluth Holdings Inc is an apparel brand in the United States. The company offers shirts, pants, and casual wear for men and women under brands like Alaskan Hardgear, Armachillo, Ballroom, Cab Commander, Crouch Gusset, Dry on the Fly, Duluth Trading Co, Duluthflex, Fire Hose, Longtail T, No Polo Shirt, No Yank, Wild Boar, and others. The Company's revenue consists of the sale of apparel, footwear, and hard goods. The company operates in a single operating segment.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.